Serous Carcinoma: Types, Symptoms, and Treatment

Serous carcinoma is an aggressive type of cancer that most commonly arises in the ovary, fallopian tube, or uterine lining, and it accounts for the majority of deaths from gynecologic cancers. The disease comes in several distinct forms that differ sharply in their biology, behavior, and response to treatment. Knowing which type you are dealing with matters enormously, because the genetic drivers, pace of progression, and drug options can be strikingly different from one subtype to the next.

High-Grade and Low-Grade Serous Ovarian Carcinoma

The two main subtypes of serous ovarian cancer are high-grade serous carcinoma (HGSOC) and low-grade serous carcinoma (LGSC). Despite sharing a name, they are essentially different diseases. HGSOC is the far more common variety, making up roughly three-quarters of all epithelial ovarian cancers. It grows quickly, is genetically unstable, and is defined at the molecular level by mutations in the TP53 gene. Researchers reviewing data from The Cancer Genome Atlas concluded that virtually all true high-grade serous carcinomas carry TP53 mutations or deletions, to the point that a tumor lacking any TP53 alteration should be reconsidered for a different diagnosis.¹ About half of HGSOC tumors also carry defects in the homologous recombination DNA repair pathway, including BRCA1 and BRCA2 mutations, which has major implications for treatment.²

Low-grade serous carcinoma, by contrast, is uncommon and follows a completely different playbook. It tends to grow slowly, affects younger women, and is driven by mutations in the KRAS and BRAF genes rather than TP53.³ These tumors are often estrogen-receptor positive, which opens the door to hormonal treatments that are rarely useful in HGSOC.⁴ LGSC develops through a slow, stepwise process that starts with a benign serous growth and progresses through a borderline tumor before becoming invasive.⁵ While LGSC has a better prognosis year to year compared with HGSOC, it is stubbornly resistant to standard chemotherapy, meaning the overall picture is more complicated than “low-grade equals less dangerous.”

Where Serous Ovarian Cancer Actually Begins

For decades, textbooks taught that ovarian cancer started on the surface of the ovary. That understanding has been overturned. Research now shows that most high-grade serous carcinomas originate not in the ovary itself but in the fallopian tube. The earliest recognizable precursor is a microscopic lesion called a serous tubal intraepithelial carcinoma, or STIC, which sits in the lining of the fallopian tube’s fimbriated (finger-like) end.⁵ Evolutionary analyses of tumor genomes suggest there can be a window of roughly seven years between the development of a STIC and the appearance of a detectable cancer in the ovary, after which spread to other sites tends to follow quickly.⁶

This discovery has had real clinical consequences. Because the fallopian tube is the likely source, removing the tubes during unrelated pelvic or abdominal surgeries (a strategy called opportunistic salpingectomy) has emerged as a potential way to prevent HGSOC in women who are finished having children. A study of over 600 HGSOC patients found that more than half had undergone at least one prior abdominal or pelvic surgery, with a median of 30 years between that earlier operation and their cancer diagnosis. Among gynecologic procedures, tubal ligation was the most common, and among general surgery procedures, gallbladder removal was the most frequent.⁷ Each of those earlier operations represented a missed chance to remove the fallopian tubes and potentially prevent a future cancer. Gynecologic societies in several countries now recommend discussing salpingectomy with patients undergoing pelvic surgery for other reasons.

Uterine Serous Carcinoma

Serous carcinoma can also arise in the uterus, where it accounts for a disproportionate share of endometrial cancer deaths despite being relatively uncommon among uterine cancers overall. Uterine serous carcinoma (USC) shares molecular features with HGSOC, including near-universal TP53 mutations. One study found that a co-existing TP53 mutation was present in about 94% of HER2-amplified endometrial carcinomas, underscoring how tightly linked TP53 alterations are to high-grade behavior in both the ovary and the uterus.⁸

An important distinction in USC is the frequency of HER2 gene amplification, which occurs in roughly one in five cases.⁹ HER2 status matters because it opens up a targeted treatment option that has improved survival for these patients, as discussed below. Testing every USC tumor for HER2 amplification is now considered standard practice.

Symptoms and Early Detection Challenges

One of the cruelest features of serous carcinoma, particularly the ovarian variety, is that symptoms tend to be vague and easily attributed to other conditions. The most common complaints are abdominal pain, bloating, a hard or distended abdomen, and feeling full quickly. A case-control study found that a four-symptom index combining abdominal pain, abdominal distension, a palpable mass, and abnormal vaginal bleeding could identify localized ovarian carcinoma with about 74% sensitivity and 71% specificity.¹⁰ That sounds reasonable on paper, but in everyday practice these symptoms overlap with dozens of benign conditions, from irritable bowel syndrome to menopause.

Data from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) offer a closer look at what happens before diagnosis. Nearly half of women later found to have invasive ovarian cancer had reported symptoms when questioned beforehand. Among those with early-stage HGSOC, gastrointestinal complaints such as changes in bowel habits and dyspepsia, as well as systemic symptoms like fatigue, were more common than in women diagnosed through routine clinical pathways.¹¹ Yet even with these clues, most ovarian cancers are still found at an advanced stage. Five-year survival drops from over 90% for early-stage disease to around 20% for advanced-stage disease.¹²

For uterine serous carcinoma, abnormal vaginal bleeding is the most common presenting symptom, particularly in postmenopausal women. While this symptom prompts evaluation more readily than the diffuse abdominal complaints of ovarian cancer, USC can still escape early detection because it sometimes arises in a thin, atrophic-looking endometrium that imaging may not flag as suspicious.

How These Cancers Are Diagnosed

Diagnosis of ovarian serous carcinoma typically involves a combination of imaging, blood tests, and ultimately tissue biopsy. The blood marker CA-125 has been the workhorse tumor marker for decades. It is elevated in many cases of epithelial ovarian cancer, and along with ultrasound findings such as a large or complex adnexal mass, it guides the initial workup.¹³ A second marker, HE4, adds accuracy when combined with CA-125. One study found that combining CA-125, HE4, and MRI together reached about 97% accuracy in distinguishing malignant from benign ovarian tumors before surgery.¹⁴ Neither marker alone is reliable enough for screening in the general population, but they are useful once suspicion has already been raised.

For uterine serous carcinoma, the standard path to diagnosis runs through endometrial biopsy or dilation and curettage, usually prompted by postmenopausal bleeding. Enhanced CT imaging in combination with CA-125 and HE4 has also shown promise for assessing how far endometrial cancer has spread, particularly in evaluating lymph node involvement.¹⁵ The definitive diagnosis in all cases requires a pathologist examining tissue under the microscope and running molecular tests to confirm the specific subtype.

Surgery as the Foundation of Treatment

For both ovarian and uterine serous carcinomas, surgery is the cornerstone of initial treatment. In ovarian cancer, the goal is complete cytoreduction, meaning the removal of all visible tumor. This usually involves removing the uterus, both ovaries, the fallopian tubes, the omentum (a fatty tissue apron in the abdomen), and any other visible tumor deposits. The amount of tumor left behind after surgery is one of the strongest predictors of how long a patient will live.

When the disease is too extensive for upfront surgery, oncologists often start with a few cycles of chemotherapy (called neoadjuvant chemotherapy) and then perform interval debulking surgery once the tumor has shrunk. A scoring system called the Chemotherapy Response Score, applied to omental tissue removed during interval surgery, can help predict outcomes. Patients whose tumors showed a near-complete or complete response to chemotherapy (a high CRS) had dramatically longer survival compared with those whose tumors showed minimal response.¹⁶

For low-grade serous carcinoma, complete surgical removal of visible disease is equally critical, and some researchers argue it matters even more given the limited benefit these tumors derive from chemotherapy.¹⁷

Chemotherapy for High-Grade Serous Carcinoma

After surgery, the standard first-line chemotherapy for HGSOC is a combination of carboplatin and paclitaxel, given every three weeks. This regimen has been the backbone of treatment for years.¹⁸ A Japanese trial showed that giving paclitaxel weekly (dose-dense scheduling) instead of every three weeks improved survival, but subsequent trials in other populations failed to replicate the benefit, leaving some uncertainty about who gains from the more intensive schedule.¹⁸ A subgroup analysis from that Japanese trial suggested that a specific molecular subtype of HGSOC, called the mesenchymal transition subtype, was the one that benefited most from dose-dense treatment.¹⁹

Tumor genetics influence how well chemotherapy works. Patients with BRCA1/2 germline mutations tend to respond better and have longer treatment-free intervals after carboplatin-paclitaxel compared with non-carriers. On the other hand, certain molecular features predict poor chemotherapy response: amplification of the CCNE1 gene, a specific TP53 mutation (R175H), and RB1 mutations were all associated with resistance to standard chemotherapy in one study.²⁰

PARP Inhibitors in High-Grade Disease

The arrival of PARP inhibitors has been one of the most meaningful advances in ovarian cancer treatment in the past decade. These drugs work by blocking an enzyme that cancer cells rely on to repair everyday DNA damage. In tumors that already have faulty DNA repair from BRCA mutations or similar defects, adding a PARP inhibitor tips the balance and causes cancer cells to accumulate lethal damage.² Three PARP inhibitors (olaparib, niraparib, and rucaparib) have been used in HGSOC, including as maintenance therapy after chemotherapy, and have extended both progression-free and overall survival.²¹

The benefit is most dramatic in patients with BRCA mutations. A meta-analysis found that maintenance PARP inhibitor therapy reduced the risk of disease progression by roughly 70 to 78% in patients with germline BRCA1 or BRCA2 mutations, compared with placebo. Even in patients without BRCA mutations, PARP inhibitors still provided meaningful benefit: those with other DNA repair defects saw about a 59% reduction in progression risk, and those with no detectable repair defect still saw about a 36% reduction.²² This is why molecular testing at diagnosis, including BRCA testing and broader homologous recombination deficiency testing, has become a standard part of care for every HGSOC patient.

Treating Low-Grade Serous and Uterine Serous Carcinomas

Low-grade serous ovarian carcinoma is notoriously resistant to platinum-based chemotherapy, and the effectiveness of standard regimens in this setting has been questioned for years.²³ Because most LGSC tumors express estrogen receptors, hormonal therapies such as aromatase inhibitors and tamoxifen are increasingly used as maintenance treatment or for recurrent disease. These drugs tend to stabilize the cancer rather than shrink it dramatically, but they come with far fewer side effects than chemotherapy. The biggest excitement in LGSC has come from targeted agents aimed at the MAP kinase pathway. The MEK inhibitor trametinib has shown activity against LGSC that exceeded what chemotherapy or hormonal therapy could achieve in clinical trials.¹⁷ CDK 4/6 inhibitors and PI3K inhibitors are also being studied in combination with hormonal agents.²³

Uterine serous carcinoma has its own targeted treatment story, centered on HER2. A randomized trial found that adding trastuzumab (a HER2-targeting antibody) to standard carboplatin-paclitaxel chemotherapy in women with HER2-positive USC nearly doubled progression-free survival, from 8 months to about 12.6 months.²⁴ Updated data showed an overall survival advantage too, with the trastuzumab group living a median of about 30 months compared with roughly 24 months in the control group.²⁵ Adding trastuzumab to chemotherapy is now an established treatment for HER2-positive advanced or recurrent USC.²⁶

Newer Drugs for Platinum-Resistant Ovarian Cancer

When HGSOC stops responding to platinum-based chemotherapy, treatment options narrow considerably. One of the most promising recent additions is mirvetuximab soravtansine, an antibody-drug conjugate that targets a protein called folate receptor alpha (FRα), which is found on the surface of many serous ovarian cancer cells. In the phase III MIRASOL trial, mirvetuximab soravtansine improved median overall survival to about 16.5 months compared with roughly 12.75 months for standard chemotherapy, along with a significantly higher response rate (about 42% versus 16%).²⁷ An earlier single-arm trial in heavily pretreated patients reported a response rate of about 32% and a median overall survival of 15 months.²⁸ These results represent a genuine step forward for patients who had few good options.

Other experimental strategies are also being explored. A checkpoint kinase 1 (CHK1) inhibitor called prexasertib showed a roughly 31% response rate in BRCA wild-type platinum-resistant HGSOC in a phase 2 trial, with a disease control rate above 56%.²⁹ Meanwhile, laboratory research is investigating whether epigenetic drugs such as azacitidine, which can switch on silenced genes, might prime platinum-resistant tumors to respond to immunotherapy by activating immune-related pathways in the tumor cells.³⁰ This is still preclinical work, but immunotherapy has struggled in ovarian cancer so far, and finding ways to make tumors more responsive is a major area of research.

Life After Treatment

Survivorship after serous carcinoma comes with its own set of challenges that often get less attention than the cancer itself. Because treatment typically involves removing the ovaries and often the uterus, many women enter sudden surgical menopause regardless of their age. Hot flashes, vaginal dryness, difficulty with intimacy, and changes in mood can be severe and persistent. A review of these issues found that symptoms related to sexuality, intimacy, and menopause were common among ovarian cancer survivors and could affect many aspects of daily life, though a multimodal approach using different treatment strategies in combination could help.³¹ Survivorship care plans that include access to sexual health specialists, pelvic floor physical therapy, and mental health support are gaining recognition as a necessary complement to oncologic follow-up.

The psychological burden of serous carcinoma is also shaped by the high recurrence rate, particularly for HGSOC. Even among women who respond well to initial treatment, the cancer comes back in the majority of advanced-stage cases. Living with that knowledge, attending regular scans and blood draws, and managing the anxiety around each follow-up appointment is a sustained stress that deserves as much clinical attention as the physical side effects. Increasingly, survivorship programs at cancer centers are integrating psycho-oncology services, mindfulness-based stress reduction, and peer support groups specifically for women with ovarian and endometrial cancers. These programs do not change the biology of the disease, but they can meaningfully change how it feels to live with it.

1
PubMed Central. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma
2
PubMed Central. Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system
3
Gynecologic Oncology. Low-grade serous ovarian cancer: A review
4
Cancer Treatment Reviews. Low grade serous ovarian cancer – A rare disease with increasing therapeutic options
5
PubMed. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms
6
PubMed Central. High grade serous ovarian carcinomas originate in the fallopian tube
7
PubMed. Quantifying opportunities to reduce high grade serous ovarian cancer via opportunistic salpingectomy
8
Modern Pathology. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas
9
PubMed Central. HER2 evaluation in uterine serous carcinoma: diagnostic agreement between biopsy and resection samples
10
Gynecologic Oncology. Prediagnostic symptoms of ovarian carcinoma: A case-control study
11
Gynecologic Oncology. Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer – An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
12
PubMed Central. Early Diagnosis of Ovarian Cancer: A Comprehensive Review of the Advances, Challenges, and Future Directions
13
PubMed. Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist
14
Journal of Radiation Research and Applied Sciences. Serum CA125 and HE4 levels combined with magnetic resonance imaging (MRI) in the clinical diagnostic value of ovarian neoplasms
15
PubMed Central. Tumor biomarkers HE4 and CA125 alongside enhanced computed tomography imaging in assessing lymph node metastasis in endometrial cancer
16
PubMed Central. Prognostic Significance of Chemotherapy Response Score in Patients Undergoing Interval Debulking Surgery
17
Endocrine-Related Cancer. New therapeutic opportunities for women with low-grade serous ovarian cancer
18
PubMed Central. Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer
19
Gynecologic Oncology. The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma
20
PubMed. Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients
21
PubMed Central. PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
22
PubMed. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer
23
PubMed Central. Targeted Therapies in Low-Grade Serous Ovarian Cancers
24
PubMed. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
25
Clinical Cancer Research. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu
26
PubMed. Targeted Therapies in the Treatment of Uterine Serous Carcinoma
27
PubMed. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
28
PubMed Central. Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial
29
Nature Communications. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
30
PubMed Central. Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
31
American Journal of Obstetrics and Gynecology. Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer